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B cells participate in the priming of the allo- and autoimmune
responses, and their depletion can thus be advantageous for islet
transplantation. Herein, we provide an extensive study of the effect
of B-cell depletion in murine models of islet transplantation. Islet
transplantation was performed in hyperglycemic B-cell–deﬁcient
(mMT) mice, in a purely alloimmune setting (BALB/c into hyper-
glycemic C57BL/6), in a purely autoimmune setting (NOD.SCID
into hyperglycemic NOD), and in a mixed allo-/autoimmune set-
ting (BALB/c into hyperglycemic NOD). Inotuzumab ozogamicin
murine analog (anti-CD22 monoclonal antibody conjugated with
calicheamicin [anti-CD22/cal]) efﬁciently depleted B cells in all
three models of islet transplantation examined. Islet graft survival
was signiﬁcantly prolonged in B-cell–depleted mice compared with
control groups in transplants of islets from BALB/c into C57BL/6
(mean survival time [MST]: 16.5 vs. 12.0 days; P = 0.004), from
NOD.SCID into NOD (MST: 23.5 vs. 14.0 days; P = 0.03), and from
BALB/c into NOD (MST: 12.0 vs. 5.5 days; P = 0.003). In the BALB/c
into B-cell–deﬁcient mice model, islet survival was prolonged as
well (MST: mMT = 32.5 vs. WT = 14 days; P = 0.002). Pathology
revealed reduced CD3
+ cell islet inﬁltration and conﬁrmed the ab-
sence of B cells in treated mice. Mechanistically, effector T cells
were reduced in number, concomitant with a peripheral Th2 proﬁle
skewing and ex vivo recipient hyporesponsiveness toward donor-
derived antigen as well as islet autoantigens. Finally, an anti-CD22/
cal and CTLA4-Ig–based combination therapy displayed remarkable
prolongation of graft survival in the stringent model of islet trans-
plantation (BALB/c into NOD). Anti-CD22/cal–mediated B-cell de-
pletion promotes the reduction of the anti-islet immune response in
various models of islet transplantation. Diabetes 61:155–165, 2012
B
cells traditionally have been investigated for their
impact on hyperacute and chronic rejection (1–3)
by virtue of their capacity to produce alloanti-
bodies (4). In the past decade, investigators have
focused on the antigen-presenting function of B cells in
the priming of autoimmunity (5,6) and activation of allo-
and autoreactive T cells (7–12). This notion is emphasized
by two recent works from Yale University (11) and from
our group (9), which demonstrate that B-cell–depletion
strategies are capable of reversing established diabetes in
NOD mice. B cells have been shown to be crucial players in
the indirect allorecognition pathway as well by displaying
a remarkable ability to capture alloantigens and activate
alloreactive T cells (5,13). Indeed, Noorchashm et al. (5)
demonstrated prolongation of heart allograft survival, dis-
ruption of antibody production, and a decrease in CD4
+
T-cell activation in a chimeric model of B-cell–restricted MHC
class II–mediated antigen presentation deﬁciency. In the wake
of these ﬁndings, authors have directed their attention to
B-cell–depleting strategies to prolong graft survival (14–17).
Among all transplant models, islet transplantation is of
particular interest in applying a B-cell–based depleting
strategy because islets endure attack from the allo- and
autoimmune responses (18–20), but it is surprising that
a systemic study of the role of B cells in murine models of
islet transplantation is lacking. Indeed, treatment with anti-
CD20 monoclonal antibody (mAb)—speciﬁcally, rituximab—
in association with antithymocyte globulin induction,
followed by a sirolimus-based immunosuppressive regimen,
was found to improve long-term islet allograft survival in the
nonautoimmune model of nonhuman primates (10), and a
B-cell–depletion strategy is currently under investigation
in a phase II clinical trial (NCT00468442). We have recently
proposed the use of a B-cell–targeted cytotoxic immuno-
conjugate in autoimmune diabetes (anti-CD22 conjugated
to calicheamicin, anti-CD22/cal or inotuzumab ozogamicin
murine analog) capable of achieving complete depletion of
B cells in peripheral blood, spleen, bone marrow, and lymph
nodes (21). Given that CD22 also is expressed on CD138
+
plasma cells, this compound also has a potential effect on
autoantibody production (9). Thus, we aimed to examine the
effect of an inotuzumab ozogamicin murine analog–based
B-cell–depletion strategy (anti-CD22/cal) in three differ-
ent models of islet transplantation (BALB/c into C57BL/6,
NOD.SCID into NOD, and BALB/c into NOD) in which allo-
and autoimmune responses, separately or jointly, are re-
sponsible for the destruction of islet grafts (22,23). This
approach will ultimately allow us to distinguish the beneﬁcial
effects of B-cell depletion on the different paths of the anti-
islet immune response. Finally, we propose a novel and highly
translational immunosuppressive strategy in islet trans-
plantation with the goal of completely inhibiting indirect
alloantigen presentation, based on the disruption of both
primary aspects of antigen presentation (i.e., B-cell–mediated
and dendritic cell [DC]-mediated T-cell activation).
RESEARCH DESIGN AND METHODS
Mice. Female C57BL/6, BALB/c, B6.C.H-2bm12 (bm12), NOD, and NOD.SCID
mice were obtained from The Jackson Laboratory (Bar Harbor, ME). B-cell–
deﬁcient (mMT) mice on a C57BL/6 genetic background were purchased from
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ORIGINAL ARTICLEThe Jackson Laboratory as well. CD4
+ T-cell receptor transgenic mice speciﬁc
for I-Abm12 expressed on bm12 mice (ABM) were available in our own lab-
oratory (24).
Study design and treatment protocols. The inotuzumab ozogamicin murine
analog compound (anti-CD22/cal mAb, provided by Pﬁzer) is a conjugate of an
anti-mouse CD22 mAb and N-acetyl-calicheamicin dimethyl acid (9). Three
murine models of islet transplantation were tested: 1) a purely alloimmune
setting (BALB/c islets transplanted into C57BL/6 mice) labeled as allo, 2)a
purely autoimmune setting (NOD.SCID islets transplanted into NOD mice)
labeled as auto,a n d3) a mixed allo- and autoimmune setting (BALB/c islets
transplanted into NOD mice) labeled as allo/auto. Anti-CD22/cal was admin-
istered in two injections (160 mg i.p. at days 0 and 5), as was cal treatment,
which was given at the same dosage and timing. A group of mice was left
untreated. CTLA4-Ig was administered to NOD mice using the following pro-
tocol: 500 mg on day 0 and 250 mg on days 2, 4, 6, 8, and 10. NOD mice were
transplanted after a minimum of 7 to a maximum of 14 days from the onset of
hyperglycemia to avoid a possible confounding effect, since we demonstrated
that diabetes may be reverted by B-cell depletion within 3 days from the onset
of hyperglycemia (9). When required, streptozotocin-induced diabetic or spon-
taneously hyperglycemic NOD mice were kept alive by insulin pellet.
ELISpot and Luminex. ELISpot (BD Biosciences, San Jose, CA) and Luminex
assays (Millipore, Billerica, MA) were performed, as described, to measure
cytokines (25).
Statistical analysis. Data are expressed as means 6 SEM. Kaplan-Meier
analysis was used for survival analysis. To compare groups, we used a two-sided
unpaired Student t test (for parametric data) or Mann-Whitney U test (for
nonparametric data) according to distribution. P , 0.05 (by two-tailed testing)
was considered an indicator of statistical signiﬁcance. Data were analyzed
with an SPSS statistical package for Windows (SPSS, Chicago, IL).
RESULTS
Inotuzumab ozogamicin murine analog (anti-CD22/
cal) depletes B cells in islet-transplanted mice. We
ﬁrst evaluated the effect of islet transplantation on pe-
ripheral B-cell numbers. In chemically (streptozotocin)
induced hyperglycemic C57BL/6 mice receiving BALB/c
islets, the percentage of splenic B220
+ cells remained un-
changed at days 7, 14, and 28 after islet transplantation
(data not shown). To assess whether treatment with anti-
CD22/cal was able to efﬁciently deplete B cells in murine
models, we performed islet transplantation in three different
immune settings: 1) a purely alloimmune setting (BALB/c
islets into chemically induced hyperglycemic C57BL/6 mice)
or allo, 2) a purely autoimmune setting (NOD.SCID islets
into spontaneously hyperglycemic NOD mice) or auto, and
3) a mixed allo- and autoimmune setting (BALB/c islets
into spontaneously hyperglycemic NOD mice) or allo/auto.
The percentage of B cells in the spleens of mice treated
with anti-CD22/cal (160 mg i.p., at days 0 and 5) or cal
(160 mg i.p., at days 0 and 5) or untreated was evaluated
at different time points by ﬂuorescence-activated cell sorter
analysis (Fig. 1). In all three models of islet transplantation,
anti-CD22/cal treatment depleted B cells up to 14 days after
transplantation (Fig. 1). In cal-treated mice (in C57BL/6 but
not NOD recipient mice), a small B-cell depletion was ev-
ident. Of note, a strain-dependent effect with regard to the
efﬁcacy of B-cell depletion was observed. Indeed, a less
profound depletion was evident in anti-CD22/cal–treated
C57BL/6 mice receiving BALB/c islets (Fig. 1A, 3), com-
pared with NOD mice receiving NOD.SCID or BALB/c (Fig.
1B, 3 and C, 3). The full recovery of B cells after anti-CD22/
cal treatment was observed at ;8 weeks after transplantation
in both C57BL/6 and NOD mice (data not shown).
B-cell depletion and B-cell deﬁciency prolong islet
graft survival without inducing tolerance. We evalu-
ated the effect of anti-CD22/cal–mediated B-cell depletion
on islet allograft survival in the three aforementioned
settings of the immune response (Fig. 2A–D). In allo, un-
treated and control antibody (cal)-treated mice invariably
rejected allografts (mean survival time [MST]: untreated =
14.0 days; cal = 12.0 days; NS) (Fig. 2A), whereas mice that
were B-cell depleted with anti-CD22/cal treatment displayed
a slight prolongation in allograft survival compared with
controls (MST: anti-CD22/cal = 16.5 days; anti-CD22/cal vs.
all, P , 0.05) (Fig. 2A). In auto, mice treated with anti-
CD22/cal showed a signiﬁcant delay in syngeneic islet graft
rejection compared with both cal-treated and untreated
mice (MST: anti-CD22/cal = 23.5 days; untreated = 14.0 days;
cal = 15.0 days; anti-CD22/cal vs. all, P , 0.05) (Fig. 2B). In
allo/auto, in which both auto- and alloimmunity exert their
effects, untreated and cal-treated mice rapidly rejected islet
grafts within a few days after transplantation, whereas B-cell–
depleted mice displayed signiﬁcant prolongation of graft
survival (MST: anti-CD22/cal = 12.0 days; untreated = 5.5;
cal = 7.5 days; anti-CD22/cal vs. all, P , 0.05) (Fig. 2C). To
study the effect of the absence of B cells on islet allograft
survival, we transplanted BALB/c islets into genetically
B-cell–deﬁcient mMT mice (on a C57BL/6 background); in
this setting, islet rejection was signiﬁcantly delayed com-
pared with wild-type (WT) control mice (MST: WT = 14.0
vs. mMT = 32.5 days; P = 0.002), but none of the islet-
transplanted mice achieved graft tolerance (Fig. 2D).
B-cell depletion preserves islet morphology. Islet grafts
were analyzed at different time points in the three afore-
mentioned immune settings of islet transplantation to eval-
uate the effect of B-cell depletion on the quality of graft
structure and islet inﬁltrate. Grafts from BALB/c into C57BL/6
and NOD.SCID into NOD transplants were collected 14 days
after transplantation, whereas BALB/c into NOD transplant
grafts were collected at day 7 (the average time of rejection
of control mice was chosen) (Fig. 3). In allo, mice treated
with anti-CD22/cal (Fig. 3A, 1–5) displayed preserved islet
structure with a mild CD3
+ cell inﬁltrate and no B220
+ cells
in the graft compared with control treated mice (Fig. 3B, 1–5).
In auto, anti-CD22/cal–treated mice showed a clear preser-
vation of islet structure with some CD3
+ cells surrounding
the islets, few B220
+ and FoxP3
+ cells, and a clear insulin-
positive cell staining (Fig. 3C, 1–5). Cal-treated mice (Fig.
3D, 1–5) maintained preservation of islet structure with
some insulin staining and abundant CD3
+ and B220
+ cells
inﬁltrating the graft. In allo/auto at day 7, islet morphol-
ogy was maintained in anti-CD22/cal–treated mice (Fig.
3E, 1–5), with clear insulin staining but several CD3
+ cells
(and some B220
+ cells) inﬁltrating the graft. Conversely,
cal-treated mice (Fig. 3F, 1–5) displayed an equal distri-
bution of CD3
+ and B220
+ cells throughout the islet graft,
resulting in a complete disruption of islet architecture and
few remaining insulin-positive cells in the remnants of
b-cells.
B-cell depletion halts the expansion of effector
T cells. We studied the effect of B-cell depletion on the
immune system and particularly on effector T cells (Teffs)
and regulatory T cells (Tregs) 14 days after islet trans-
plantation in allo and auto and at day 7 in allo/auto. Teffs
and Tregs were quantiﬁed in the spleens of anti-CD22/
cal–treated, cal-treated, or untreated mice. In allo, anti-
CD22/cal–treated mice displayed a signiﬁcant reduction in
CD4
+CD44
hiCD62L
low (CD4
+ effector) cell number com-
pared with control mice (anti-CD22/cal = 4.68 3 10
7 6 6.8 3
10
6; untreated = 11.6 3 10
7 6 5.6 3 10
6;c a l=8 . 43 10
7 6
5.2 3 10
6, absolute number of cells; anti-CD22/cal vs. all,
P , 0.05) (Fig. 4A, 1), whereas cal-treated mice showed
a partial reduction in CD4
+ effector cell number (cal vs.
untreated, P = 0.01) (Fig. 4A, 1). No differences in the
number of peripheral CD8
+CD44
hiCD62L
low (CD8
+ effector)
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this model, B-cell depletion is associated with an overall
reduction of peripheral CD4
+CD25
+FoxP3
+ (Tregs) both in
anti-CD22/cal– and cal alone–treated mice compared with
untreated mice (Fig. 4A, 3). In auto, no signiﬁcant differ-
ences in the absolute numbers of Teffs and Tregs were
evident among the three groups of mice studied (Fig. 4B,
1–3). Indeed, anti-CD22/cal treatment did not affect CD4
+
and CD8
+ Teff number, nor did it affect Treg number. In
allo/auto, a reduction in the absolute number of Teffs was
found in anti-CD22/cal–treated mice compared with cal-
treated and untreated mice. Both CD4
+ and CD8
+ Teffs
(Fig. 4C, 1–2) were reduced in anti-CD22/cal–treated mice,
whereas no differences were evident in the absolute number
of Tregs (Fig. 4C, 3).
B-cell depletion reshapes the peripheral cytokine proﬁle
by skewing Th1 to Th2. We then evaluated the effect of
B-cell depletion on peripheral cytokine proﬁle after islet
transplantation using the Luminex assay. In allo 14 days
after islet transplantation, peripheral levels of the Th1 cyto-
kine g-interferon (IFN-g) were reduced in the anti-CD22/cal–
treated group, whereas an increase in peripheral levels of
the Th2 cytokines interleukin (IL)-4 and IL-10 was evident
(Fig. 5A, 1). No differences in the proinﬂammatory cyto-
kines IL-6, IL-2, and IL-15 peripheral levels were noted
(Fig. 5A, 1). In auto, no polarization of the immune response
was observed by serum analysis after transplantation (Fig.
5B, 1). In this model, peripheral levels of Th1, Th2 (IL-4
and IL-10), and proinﬂammatory cytokines (IL-6) were un-
affected by B-cell depletion. In allo/auto 7 days after islet
transplantation, an overall suppression of the Th1 response
was evident, with B-cell–depleted mice showing lower
peripheral levels of IFN-g (anti-CD22/cal = 4.2 6 2.1 pg/mL;
untreated = 52.5 6 11.1 pg/mL; cal = 24.9 6 5.5 pg/mL; anti-
CD22/cal vs. all, P , 0.01) (Fig. 5C, 1). Moreover, B-cell–
depleted mice showed an increase in peripheral levels of
the Th2 cytokines IL-4 (anti-CD22/cal = 1.1 6 0.1 pg/mL;
untreated = 0.5 6 0.1 pg/mL; cal = 1.0 6 0.1 pg/mL; anti-
CD22/cal vs. untreated, P , 0.0001) and IL-10 (anti-CD22/
cal = 5.5 6 2.3 pg/mL; untreated = 1.5 6 0.3 pg/mL; cal =
1.0 6 0.0 pg/mL; anti-CD22/cal vs. untreated, P = 0.03),
thus conﬁrming the skewing of Th1 to Th2 immune response
(Fig. 5C, 1). Finally, proinﬂammatory cytokines IL-2 (anti-
CD22/cal = 1.6 6 0.3 pg/mL; untreated = 1.2 6 0.1 pg/mL;
cal = 11.0 6 2.9 pg/mL; anti-CD22/cal vs. cal, P =0 . 0 0 9 )a n d
IL-6 (anti-CD22/cal = 11.7 6 1.4 pg/mL; untreated = 24.4 6 2.1
FIG. 1. Anti-CD22/cal–mediated B-cell depletion in three immune settings of islet transplantation (allo, auto, and allo/auto). The percentage of
B220
+ cells was analyzed in the spleen of C57BL/6 and NOD mice at baseline and at 14 days after islet transplantation (n = 4 mice/condition). 1)I n
allo, BALB/c islets were transplanted into chemically induced C57BL/6 mice and treated with anti-CD22/cal, cal alone, or were left untreated (A1–5).
Robust depletion of B220
+ cells was evident 14 days after transplantation in mice treated with anti-CD22/cal compared with naïve untransplanted
mice (baseline) (#P < 0.0001) and control antibody (cal)-treated mice (*P < 0.0001) (A1–5). 2) In auto, NOD.SCID islets were transplanted under
the kidney capsule of spontaneously hyperglycemic NOD mice (B1–5). Complete B-cell depletion was observed 14 days after transplantation in
mice treated with anti-CD22/cal compared with naive untransplanted (#P < 0.0001) and control-treated mice (*P < 0.0001) (B1–5), whereas no
depleting effect was found when mice were treated with cal or were untreated (NS). 3) In allo/auto, BALB/c islets were transplanted into
spontaneously hyperglycemic NOD mice (C1–5). A complete B-cell depletion occurred 14 days after transplantation in mice treated with anti-
CD22/cal compared with untransplanted (#P < 0.0001), cal-treated (*P < 0.0001), and untreated mice (*P < 0.0001) (C1–5), whereas no dif-
ferences in B-cell peripheral percentage were observed in mice treated with cal or untreated (NS) (C4–5).
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0.01) were reduced compared with controls (Fig. 5C, 1).
B-cell depletion promotes antidonor hyporesponsiveness.
We also examined the effect of B-cell depletion on in vitro
rechallenge with donor-derived alloantigens or islet-derived
autoantigens using the ELISpot assay. In allo, splenocytes
from transplanted mice were harvested 14 days after islet
transplantation and rechallenged ex vivo with donor-
derived antigen (i.e., BALB/c irradiated splenocytes) to
stimulate an antidonor-speciﬁc alloimmune response. Anti-
CD22/cal–treated mice displayed a reduction in global re-
sponsiveness toward alloantigens with a skewing of the
Th1 response toward a Th2 proﬁle. IFN-g–producing cells
were substantially reduced in B-cell–depleted mice (anti-
CD22/cal = 84.6 6 10.3; untreated = 404.3 6 34.2; cal =
345.3 6 125.7, counted as number of IFN-g–producing
cells per 5 3 10
5 total splenocytes; anti-CD22/cal vs. all,
P , 0.05), with an increase in IL-4–producing cells (anti-
CD22/cal = 293.6 6 24.5; untreated = 133.3 6 27.2; cal =
174.8 6 28.1, counted as number of IL-4–producing cells
per 5 3 10
5 total splenocytes; anti-CD22/cal vs. all, P ,
0.05) (Fig. 5A, 2–3). In auto, the rechallenge of splenocytes 14
days after transplantation with islet autoantigens (i.e., BDC2.5
and islet-speciﬁc glucose-6-phosphatase catalytic subunit-
related protein [IGRP]) did not show any differences in re-
sponsiveness toward autoantigens in anti-CD22/cal–treated,
untreated, or cal-treated mice (Fig. 5B, 2). In allo/auto,
splenocytes from transplanted mice 7 days after trans-
plantation were rechallenged ex vivo with donor-derived
antigen (i.e., BALB/c irradiated splenocytes) and islet-derived
peptides. The ex vivo challenge with alloantigens con-
ﬁrmed that B-cell–depleted mice were donor hypores-
ponsive, with fewer IFN-g–producing cells (anti-CD22/
cal = 224.5 6 49.7; untreated = 426.5 6 66.9; cal = 352.0 6
24.5, counted as number of IFN-g–producing cells per 5 3
10
5 total splenocytes; anti-CD22/cal vs. all, P , 0.05) and
more IL-4–producing cells (anti-CD22/cal = 402.2 6 91.2;
untreated = 227.0 6 13.9; cal = 199.1 6 22.0, counted as
number of IL-4–producing cells per 5 3 10
5 total spleno-
cytes; anti-CD22/cal vs. all, P , 0.05) (Fig. 5C, 2 and 4).
These results were conﬁrmed by ex vivo challenge of sple-
nocytes harvested from islet-transplanted mice with CD4
+
and CD8
+ T-cell–restricted islet peptides (BDC2.5 and IGRP,
respectively), demonstrating hyporesponsiveness toward
autoantigens as well as a clear shift from a Th1 to a Th2
immune response in B-cell–depleted mice compared with
both untreated and cal-treated controls (Fig. 5C, 3 and 5).
B-cell absence induces Th1 to Th2 skewing in vitro.
To provide clear evidence of the link between the absence of
B cells and the skewing of the immune system from a Th1
toward a Th2 response, we performed an in vitro mixed-
lymphocytes reaction where 0.5 3 10
6 irradiated splenocytes
of BALB/c mice were challenged with 0.5 3 10
6 splenocytes
harvested from B-cell–deﬁcient (mMT) or C57BL/6 WT mice
FIG. 2. Islet graft survival in B-cell–deﬁcient (mMT) and B-cell–depleted (anti-CD22/cal) mice in the three immune settings of islet transplantation
(allo, auto, and allo/auto). 1) In allo, a delay in graft rejection was evident in B-cell–depleted mice compared with control-treated and untreated
mice (P = 0.004) (A). 2) In auto, a prolongation of syngeneic graft survival was observed in B-cell–depleted mice compared with cal-treated (P =
0.006) and untreated mice (P = 0.03) (B). 3) In allo/auto, delayed graft rejection was achieved in B-cell–depleted mice compared with cal-treated
(P = 0.003) and untreated mice (P = 0.001) (C). 4) When BALB/c islets were transplanted in chemically induced C57BL/6 B-cell–deﬁcient mice,
islet graft survival was signiﬁcantly prolonged compared with WT C57BL/6 mice (P = 0.002) (D).
B-CELL DEPLETION IN ISLET TRANSPLANTATION
158 DIABETES, VOL. 61, JANUARY 2012 diabetes.diabetesjournals.orgin an ELISpot assay. The number of IFN-g–producing cells
was similar between the two groups (WT = 115 6 28; B-cell
deﬁcient = 139 6 28 number of IFN-g–producing cells; NS),
whereas the number of IL-4–producing cells increased in the
absence of B cells (WT = 104 6 20; B-cell deﬁcient = 493 6
48 number of IL-4–producing cells; P = 0.001) (Fig. 6A),
with a lower IFN-g–to–IL-4 ratio (WT = 1.2 6 0.2; B-cell de-
ﬁcient = 0.2 6 0.03 IFN-g–to–IL-4 ratio; P = 0.009) (Fig. 6B).
Combinational targeting of indirect antigen presen-
tation with B-cell depletion and CTLA4-Ig prolongs
islet allograft survival in NOD mice. We sought to ﬁnd
a clinically relevant B-cell depletion–based immunosup-
pressive strategy to fully target indirect allorecognition in
NOD mice. We combined anti-CD22/cal treatment (to in-
hibit B-cell–mediated T-cell activation) and CTLA4-Ig,
a fusion protein that prevents the interaction between B7.1
and CD28 (to inhibit DC-mediated T-cell activation) (25).
CTLA4-Ig treatment alone signiﬁcantly prolonged islet
graft survival with similar kinetic as anti-CD22/cal com-
pared with untreated mice (MST: CTLA4-Ig = 13.0 days;
anti-CD22/cal = 12.0 days; untreated = 5.5 days; untreated
vs. all, P , 0.01) (Fig. 6C) and anti-CD22/cal+CTLA4-Ig
treatment was able to further prolong islet allograft sur-
vival compared with monotherapeutic anti-CD22/cal or
CTLA4-Ig (MST: anti-CD22/cal+CTLA4-Ig = 33.5 days; anti-
CD22/cal+CTLA4-Ig vs. all, P , 0.01) (Fig. 6C). The re-
levance of this strategy was conﬁrmed in the chemically
induced hyperglycemic B-cell–deﬁcient (mMT) mice trans-
planted with BALB/c islet, which treated with CTLA4-Ig
showed indeﬁnite islet allograft survival (data not shown). It
is interesting that anti-CD22/cal+CTLA4-Ig–treated mice
displayed a conspicuous number of peripheral reemerging
B cells at the time of rejection (Fig. 6D). Histological anal-
ysis of the grafts of these anti-CD22/cal+CTLA4-Ig–treated
mice revealed preserved islet structure and insulin staining
with severe CD3
+- and B220
+-cell inﬁltration (Fig. 6E, 1–5)
FIG. 3. Islet pathology in the three immune settings of islet transplantation (allo, auto, and allo/auto). Islets from BALB/c or NOD.SCID mice were
transplanted under the kidney capsule of chemically induced hyperglycemic C57BL/6 or spontaneously hyperglycemic NOD mice treated with anti-
CD22/cal or cal and were retrieved for histological analysis at different time points (n = 3 mice/group). Grafts from both BALB/c into C57BL/6– and
NOD.SCID into NOD–transplanted mice were collected 14 days after transplantation, whereas BALB/c into NOD grafts were collected at day 7 at
the time of graft rejection of control mice. 1) In allo at day 14, anti-CD22/cal–treated mice displayed preserved islet architecture (A1) with mild
CD3
+ cell inﬁltrate (A2), no B220
+ cells (A3), and few FoxP3
+ cells (A4). Insulin staining was clearly preserved (A5). Cal-treated and untreated
mice showed severe cellular inﬁltration with a complete disruption of islet architecture (B1) and several CD3
+ (B2) and B220
+ cells (B3); some
CD3
+ cells also coexpressed FoxP3
+ (B4). Very few cells were positive for insulin (B5). 2) In auto at day 14, anti-CD22/cal–treated mice displayed
clear preservation of islet structure (C1) with several CD3
+ cells in the inﬁltrate (C2) surrounding the islets, along with few B220
+ (C3) and
FoxP3
+ cells (C4) as well as abundant insulin-positive cells (C5). Cal-treated mice maintained preservation of islet structure (D1) with insulin-
positive cells (D5) but with a massive CD3
+ (D2) and B220
+ (D3) cell inﬁltrate and with some FoxP3
+ (D4) cells evident in the islet mass. 3)I n
allo/auto at day 7, islet architecture appeared preserved in anti-CD22/cal–treated mice (E1) with clear insulin staining (E5) but with severe CD3
+
cell (E2)i n ﬁltrate and few FoxP3
+ cells (E4) surrounding the islets, whereas B cells were absent (E3). Conversely, cal-treated mice displayed
equally distributed CD3
+ (F2) and B220
+ (F3)c e l li n ﬁltration, resulting in complete disruption of islet architecture (F1) and scant insulin staining
(F5). Almost no inﬁltrating FoxP3
+ cells were evident (F4). H&E, hematoxylin-eosin. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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staining with lesser CD3
+ and B220
+ cell inﬁltration (Fig.
6F, 1–5). We then analyzed the frequency of Teffs and
Tregs in the spleens of transplanted mice at the time of
rejection, and a reduction in the number of CD8
+ effector
cells was observed in anti-CD22/cal+CTLA4-Ig–treated
mice compared with untreated control mice (Fig. 6H),
whereas no difference was seen in the percentages of
CD4
+ effector cells (Fig. 6G) or Tregs (Fig. 6I) at the time
point examined. Moreover, splenocytes from transplanted
mice were rechallenged in vitro with donor-derived antigen
(BALB/c irradiated splenocytes), and the donor-speciﬁc
FIG. 4. Effect of B-cell depletion on the immune system in the three immune settings of islet transplantation (allo, auto, and allo/auto). Sple-
nocytes were analyzed in the three groups of islet-transplanted mice at day 14 in the BALB/c into C57BL/6 and NOD.SCID into NOD groups and at
day 7 in the BALB/c into NOD group (n = 3 mice/experiment). 1) In allo, anti-CD22/cal treatment induced a decrease in the absolute number of
CD4
+CD44
hiCD62L
low cells compared with untreated (*P = 0.0002) and cal-treated (*P = 0.01) mice (A1). Cal-treated mice, which experience
a partial B-cell depletion, displayed a signiﬁcant reduction in CD4
+CD44
hiCD62L
low cell (Teff) numbers as well (*P = 0.01) (A1). No differences in
the absolute numbers of CD8
+CD44
hiCD62L
low cells (Teffs) were observed in this model (A2). In the same immune setting, a reduction in
CD4
+CD25
+FoxP3
+ cell numbers was evident in the anti-CD22/cal–treated (*P < 0.0001) and in cal-treated (*P = 0.0006) groups compared with the
untreated group (A3). 2) In auto, no differences were evident with regard to either CD4
+CD44
hiCD62L
low or CD8
+CD44
hiCD62L
low cell numbers as
well as in the peripheral numbers of CD4
+CD25
+FoxP3
+ cells in the B-cell–depleted group compared with both untreated and cal-treated mice (B1–3).
Naïve untransplanted mice displayed reduced numbers of CD8
+CD44
hiCD62L
low T cells compared with anti-CD22/cal–treated mice (#P = 0.03)
(B2), as well as reduced numbers of CD4
+CD25
+FoxP3
+ cells compared with both anti-CD22/cal–treated (#P = 0.04) and cal-treated mice (#P =
0.03) (B3). 3) In allo/auto, anti-CD22/cal–treated mice displayed a signiﬁcant reduction in CD4
+CD44
hiCD62L
low (*P = 0.02) and
CD8
+CD44
hiCD62L
low (*P = 0.04) cell numbers (C1–2), with no signiﬁcant differences in CD4
+CD25
+FoxP3
+ cell numbers (C3).
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We observed a signiﬁcant reduction in IFN-g–producing
cells in anti-CD22/cal+CTLA4-Ig–treated mice compared
with untreated mice at the time of rejection (Fig. 6J).
Moreover, the status of the autoimmune response in trea-
ted mice was evaluated by restimulating splenocytes from
transplanted mice ex vivo with BDC2.5 (to activate the
CD4
+ autoreactive T-cell response) and IGRP (to activate
the CD8
+ autoreactive T-cell response) peptides (Fig. 6K).
We conﬁrmed that the immune response toward autoantigen
was suppressed in anti-CD22/cal+CTLA4-Ig–treated mice
compared with untreated mice at the time of rejection
(BDC2.5-stimulated IFN-g–producing cells: anti-CD22/cal
+CTLA4-Ig = 84.4 6 5.9; untreated = 129.8 6 14.5, counted
as number of IFN-g–producing cells per 1 3 10
6 total
splenocytes; P = 0.02; IGRP-stimulated IFN-g–producing
cells: anti-CD22/cal+CTLA4-Ig = 22.5 6 4.0; untreated =
48.5 6 10.5, counted as number of IFN-g–producing cells
per 1 3 10
6 total splenocytes; P =0 . 0 4 )( F i g .6 K). We
evaluated whether CTLA4-Ig is endowed with an immuno-
logic effect on B/T-cell interaction. Thus, we took advantage
of T-cell receptor transgenic mice and we plated 0.1 3 10
6
CD11c
+ or 0.2 3 10
6 B220
+ cells harvested from bm12 mice
with 0.4 3 10
6 CD4
+ cells harvested from ABM mice in an
ELISpot assay adding serial concentrations of CTLA4-Ig
(1, 10, and 100 ng/mL). We found that CTLA4-Ig inhibited,
in a dose-dependent manner, the number of IFN-g–pro-
ducing cells induced by DCs (no drug = 332 6 23; CTLA4-Ig
1 mg/mL = 127 6 29; CTLA4-Ig 10 mg/mL = 31 6 5; CTLA4-Ig
100 mg/mL = 15 6 3, counted as number of IFN-g–producing
FIG. 5. Th1 to Th2 skewing of the immune response in the three immune settings of islet transplantation (allo, auto, and allo/auto) after B-cell
depletion. Serum samples (n = 3 samples/experiment) and splenocytes (n = 3 mice/experiment) were analyzed in the three groups of islet-
transplanted mice at day 14 in the BALB/c into C57BL/6 and NOD.SCID into NOD groups and at day 7 in the BALB/c into NOD group. Peripheral
cytokine proﬁles and polarization of the auto- and alloimmune response were examined. 1) In allo, a decrease in the Th1 cytokine IFN-g (*P <
0.05) and an increase in the Th2-relevant cytokines IL-4 (*P < 0.01) and IL-10 (*P < 0.001) were evident in B-cell–depleted mice compared with
cal-treated and untreated mice (A1). These data were conﬁrmed by the ELISpot assay in which donor-derived antigens (irradiated BALB/c
splenocytes) were plated with splenocytes harvested from transplant recipients undergoing the different treatments. We found that anti-CD22/
cal–treated mice exhibit a reduced number of IFN-g–secreting cells compared with cal-treated and untreated mice (*P < 0.05) (A2), whereas IL-4–
secreting cell numbers were signiﬁcantly increased (*P < 0.05) (A3). 2) In auto, no change in peripheral cytokine levels was evident in the three
groups of mice studied (B1), and similar numbers of IFN-g– and IL-4–producing cells (B2 and B3, respectively) were observed after ex vivo
restimulation with b-cell peptides (BDC2.5 and IGRP). 3) In allo/auto, examination of the cytokine proﬁle (C1) revealed a systemic suppression of
the inﬂammatory response (IL-6, *P < 0.01) with increased levels of the Th2-relevant cytokines IL-4 (*P < 0.01) and IL-10 (*P < 0.05) and
a complete suppression in the Th1 immune response (IFN-g,* P < 0.01; IL-2, *P < 0.01). In this animal model, both the allo- and autoimmune
responses were examined (C2–5). Donor-derived antigen (BALB/c splenocytes) and islet peptides (BDC2.5 and IGRP) were plated with spleno-
cytes harvested from the three groups of mice studied at day 7 after transplantation. B-cell–depleted mice displayed reduced numbers of IFN-g–
producing cells (*P < 0.05) and increased numbers of IL-4–producing cells (*P < 0.05) among both donor-speciﬁc T cells (stimulated using BALB/c
splenocytes) (C2 and 4) and CD4
+ (BDC2.5-stimulated, *P < 0.05) and CD8
+ (IGRP-stimulated, *P < 0.05) (C3 and 5) autoreactive T cells.
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diabetes.diabetesjournals.org DIABETES, VOL. 61, JANUARY 2012 161FIG. 6. In vitro Th1 to Th2 skewing in B-cell–deﬁcient mice and combinational immunosuppressive strategy in NOD mice. BALB/c splenocytes were
challenged with B-cell–deﬁcient or C57BL/6 splenocytes. IL-4–producing cells were increased in B-cell–deﬁcient mice (n =3 )( * P = 0.001) (A) with
a reduction of IFN-g–to–IL-4 ratio (*P = 0.009) in the absence of B cells (B). Spontaneously hyperglycemic NOD mice were transplanted with
BALB/c islets and treated with anti-CD22/cal alone or in combination with CTLA4-Ig; control treatments were anti-CD22/cal and CTLA4-Ig alone
(C). Mice treated with anti-CD22/cal+CTLA4-Ig displayed prolonged islet graft survival compared with CTLA4-Ig (*P = 0.006) or anti-CD22/cal
(*P = 0.006) treatment alone (C). At almost 40 days after transplantation, B220
+ cells reemerged in the spleens of anti-CD22/cal+CTLA4-Ig NOD
mice (D). At the time of rejection, islet structure appeared well preserved in anti-CD22/cal+CTLA4-Ig–treated mice (E1). As expected, severe
inﬁltration of CD3
+ cells (E2) with some FoxP3
+ (E4) expression was evident in the graft area in anti-CD22/cal+CTLA4-Ig–treated mice. Few
B220
+ cells inﬁltrated the graft (E3), and insulin staining remained clearly preserved despite the complete loss of graft function (E5). At the day
of rejection, untreated mice displayed a complete disruption of islet architecture (F1), an equally distributed CD3
+ (F2) and B220
+ (F3) cell
inﬁltrate, few FoxP3
+ cells (F4), and scant insulin staining (F5). Splenocytes harvested from islet-transplanted NOD mice treated with anti-CD22/
cal+CTLA4-Ig or from untreated mice were analyzed at the time of rejection (n = 3 mice/experiment). The percentages of CD4
+CD44
hiCD62L
low
(G) and CD4
+CD25
+FoxP3
+ cells (I) were similar in the two groups of mice, whereas a reduction in CD8
+CD44
hiCD62L
low cells (H) was evident in
anti-CD22/cal+CTLA4-Ig–treated NOD mice (*P < 0.05). Splenocytes harvested from anti-CD22/cal+CTLA4-Ig–treated NOD mice were stimulated
with donor-derived antigen (BALB/c) or islet-speciﬁc peptides (BDC2.5 and IGRP) and compared with untreated mice at the time of rejection (n =
3 mice/experiment) (J and K). Reduced numbers of IFN-g–producing cells were evident in mice treated with the combinational strategy upon
stimulation of the alloantigen immune response (*P =0 . 0 0 3 )( J). In a similar manner, CD4
+ and CD8
+ autoreactivity to BDC2.5 (*P = 0.02) and IGRP
(*P = 0.04), respectively (K), was signiﬁcantly reduced in NOD mice treated with anti-CD22/cal+CTLA4-Ig compared with untreated NOD mice.
bm12-derived B220
+ cells were challenged with ABM-derived CD4
+ cells with serial concentrations of CTLA4-Ig (1, 10, and 100 ng/mL). IFN-g–
producing cells, 96 h after stimulation, showed a dose-dependent reduction in the presence of CTLA4-Ig (n = 3) (no drug vs. all, *P < 0.001) (L).
H&E, hematoxylin-eosin. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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6 total splenocytes; no drug vs. all, P , 0.01)
(data not shown) and B cells (no drug = 510 6 37; CTLA4-Ig
1 mg/mL = 119 6 29; CTLA4-Ig 10 mg/mL = 14 6 4; CTLA4-Ig
100 mg/mL = 2 6 0, counted as number of IFN-g–producing
cells per 1 3 10
6 total splenocytes; no drug vs. all, P ,
0.001) (Fig. 6L).
DISCUSSION
Islet transplantation represents a transplant model in which
the alloimmune response and recurrence of autoimmunity
coexist, jeopardizing long-term islet function and ultimately
leading to graft rejection (9,18,26). B cells have been shown
to have an essential role as antigen-presenting cells (APCs)
in the priming of T cells during the allo- and autoimmune
responses (6,8,27), thus constituting a suitable target to
modulate the immune response in islet transplantation
(28). It is interesting that although clinical trials based on
B-cell depletion in islet transplantation are ongoing (28),
the literature is lacking in murine studies examining the
effect of B-cell depletion in islet transplantation. Herein,
we delineate the effect of B-cell depletion in three different
models of murine islet transplantation: 1) in a purely
alloimmune setting (BALB/c into chemically induced hy-
perglycemic C57BL/6 mice), 2) in a purely autoimmune
setting (NOD.SCID into spontaneously hyperglycemic NOD
mice), and 3) in a mixed allo- and autoimmune setting
(BALB/c into spontaneously hyperglycemic NOD mice).
We used the novel B-cell–depleting agent inotuzumab ozo-
gamicin murine analog (anti-CD22/cal), which targets the
CD22 receptor and, thus, depletes mature B cells from
lymphoid organs (9,21), and cal alone, as control antibody.
We observed a nearly complete depletion of B cells in the
spleen 14 days after transplantation (depletion was more
robust in NOD mice compared with the C57BL/6 strain),
with a full recovery 8 weeks after treatment. When anti-
CD22/cal was used as B-cell–depleting agent, a signiﬁcant
delay in islet graft rejection was found in all three models
tested; however, B-cell depletion per se cannot induce
tolerance, which was conﬁrmed in B-cell–deﬁcient mMT
knockout mice. Graft pathology conﬁrmed the complete
absence of B cells in the graft inﬁltrate of the three models
tested, with a prominent CD3
+ cell inﬁltrate. Mechanistic
studies revealed that mice treated with anti-CD22/cal ex-
perienced prolongation of graft survival, with preserved
insulin staining in the graft, an overall reduction in peripheral
Teff numbers in allo and allo/auto, and hyporesponsiveness
to donor alloantigens (in allo) and to islet-derived auto-
antigens (in allo/auto), with a reshaping of the peripheral
cytokine proﬁle and an increase in IL-4 and IL-10 periph-
eral levels (Table 1). Of interest, we found that the absence
of B cells leads to a polarization of allo- and autoimmune
responses toward a Th2 response, with an inversion of
IFN-g/IL-4 production in the periphery, in the ex vivo chal-
lenge of T cells with donor-derived antigen and islet auto-
antigens and the in vitro mixed-lymphocytes reaction.
Unfortunately, the control antibody (cal), being a DNA-
damaging cytotoxic agent, showed some depleting activ-
i t yo nBa n dTc e l l s ,b u ts i n c et h e r ew a sn oe f f e c to n
islet allograft survival, we believe that this drug may be
suitable as negative control antibody for anti-CD22/cal.
Our data, for the ﬁrst time, elucidate the effect of B-cell
depletion on the immune system in three settings of islet-
transplanted mice and demonstrate that the absence of
B cells (using depletion strategies or via genetic deletion) is
not sufﬁcient to induce islet graft tolerance. We speculate
that B cells may be replaced by DCs as APCs or that the
maintenance of some regulatory B cells (28–30) may be
required to achieve graft tolerance (31,32). Indeed, our
group previously demonstrated that B cells are required to
obtain anti-CD45RB–mediated allograft tolerance and to
inhibit alloreactive T-cell activation (33). The lack of efﬁ-
cacy of B-cell depletion in prolonging islet allograft sur-
vival may be related to the fact that B cells play a more
relevant role in initial expansion of pathogenic T cells in
NOD mice, but as soon as autoreactive T cells have be-
come memory cells, B-cell depletion resulted in a limited
effect. This can also explain why depleting B cells is
slightly more effective in an alloimmune setting, in which
T cells are naïve at the time of transplantation. Our data
revealed that B-cell depletion has a mild effect in pro-
longing islet graft survival, in reducing Teffs and skewing
the immune response to Th2 proﬁle in the auto setting,
whereas autoimmune response was severely reduced in
the mixed allo/auto setting. This may suggest that the re-
duced anti-islet response in the latter recipient group could
be secondary to the suppressed alloimmune response. In
summary, we demonstrate that B-cell depletion is effective
in prolonging islet graft survival but is unable to induce
allograft tolerance. Inotuzumab ozogamicin murine analog
(anti-CD22/cal) is available for clinical use (34,35), thus
representing a translational therapeutic approach (36,37).
It is likely that depleting strategies (e.g., anti-T/B cells) are
not fully effective when used as a monotherapy because of
the redundancy of the immune response (38,39). There-
fore, to completely halt T-cell activation and block residual
APC function, we used an immunosuppressive regimen
based on the combination of B-cell depletion and CTLA4-Ig
treatment in the benchmark model of islet transplantation:
the NOD mouse (Fig. 7). CTLA4-Ig is a clinically approved
compound that prevents the interaction between CD80/
CD86 (B7.1/B7.2) and CD28, leading to a reduction in clonal
expansion, to T-cell anergy, and to inhibition of T-cell acti-
vation (40–42). In this study, we conﬁrm that CTLA4-Ig
inhibits DC/T-cell interaction in vitro, but for the ﬁrst time,
we show that B-cell–mediated T-cell activation is strongly
inhibited by CTLA4-Ig as well. Our combination strategy
TABLE 1
The effect of B-cell depletion using inotuzumab ozogamicin murine
analog (anti-CD22/cal) treatment on the anti-islet immune response
in three murine models of islet transplantation
Outcome
Immune setting
Allo Auto Allo/Auto
Graft survival ↑↑ ↑ ↑
Insulin staining/islet morphology ↑↑ ↑ ↑↑
CD4
+CD44
hiCD62L
low (CD4
+ Teffs) ↓↓ ↔ ↓
CD8
+CD44
hiCD62L
low (CD8
+ Teffs) ↓↓ ↔ ↓
CD4
+CD25
+FoxP3
+ (Tregs) ↓↔ ↔
Th1 cytokine (IFN-g) ↓↓ ↔ ↓↓
Th2 cytokines (IL-4 and IL-10) ↑↑ ↔ ↑
Proinﬂammatory cytokines (IL-6 and IL-2) ↔↔ ↓ ↓
The B-cell–depletion effect is compared with control treatment in the
three immune settings. Anti-CD22/cal treatment resulted in prolonga-
tion of islet graft survival, with preserved insulin-positive cells in the
graft (in the three immune settings), a reduction in the absolute
numbers of peripheral CD4
+ and CD8
+ effector cells (in allo and
allo/auto), hyporesponsiveness to donor-derived and islet-derived
antigens with a skewing from a Th1 to a Th2 immune response (in
allo and allo/auto), and a reduction of proinﬂammatory cytokine lev-
els (in allo/auto).
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transplantation, in which both allo- and autoimmune re-
sponses take part in the rejection process. A repeated, ex-
tended administration of a B-cell–depleting agent may be
tested in clinical trials to inhibit reemerging B-cell–mediated
chronic activation of the immune system, but because we
show that islet allograft rejection occurs before B-cell re-
covery, we believe that B cells are partially responsible for
triggering allograft rejection.
In conclusion, B-cell depletion signiﬁcantly affects allo-
and autoimmune responses, albeit to a lower extent in the
latter process. B-cell depletion in monotherapy cannot be
considered to be a tolerogenic strategy per se and must be
accompanied by complementary or synergistic immuno-
logical strategies (e.g., costimulatory blockade).
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